Biocon Ltd Share Price

Overview

Biocon Ltd share price is currently ₹403.16, down by - ₹8.00 (1.95%) from its previous closing price of ₹411.16. The share price has declined -5.81% over the past month and gained 14.05% over the past year. The stock's 52-week low and high are ₹0.00 and ₹441.70, respectively. Biocon Ltd has a market capitalisation of ₹ 67,690.00 Cr. The share price was last updated on 24 Aug 2026, 03:59 PM IST.

Biocon Ltd

BIOCON

₹0.00

- ₹8.00

1.95%

Healthcare

₹0.00(%)1D

Updated: 24 Aug 2026, 03:59:48 pm IST

Market Data

Open Price

₹402.80

Prev. Close

₹411.16

₹402.75

Day Low

₹405.40

Day High

₹0.00

52 Week Low

₹441.70

52 Week High

HealthcarePharmaceuticals & Drugs

CategoryLarge Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

120.35

Sector PE

42.03

PB Ratio

1.95

Sector PB

5.83

EPS

3.35

Dividend Yield

0.14

Today's Volume

1.837 M

5 Day Avg. Volume

2.080 M

PEG Ratio

-1.68

Market Cap.

₹ 67,690.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 10% at ₹0.5/Share	03-Jul-2026	03-Jul-2026
DividendsFinal Dividend of 10% at ₹0.5/Share	04-Jul-2025	04-Jul-2025

Mutual Fund Ownership

Mutual Fund Holder	Jun 26 Shares held	Jul 26 Shares held
SBI Contra Fund - Regular Plan - IDCW	4.01 Cr	4.01 Cr no change
SBI Large & Midcap Fund - Regular Plan - IDCW	2.00 Cr	2.35 Cr (17.5%)
Kotak Midcap Fund - Regular Plan - Growth	-	1.58 Cr (100%)
SBI Midcap Fund - Regular Plan - Growth	1.56 Cr	1.56 Cr no change
SBI Balanced Advantage Fund - Regular Plan - Growth	1.30 Cr	1.30 Cr no change

Show all holdings

About Biocon Ltd 👋

Biocon Limited is an India-based biopharmaceutical company, engaged in the manufacture of biotechnology products and research services. The Company is in the business of manufacturing active pharmaceutical ingredients (APIs) and formulations, including biosimilar drugs for diabetics, oncology and autoimmune diseases. The Company's segment includes Generics, Biosimilars, Novel Biologics and Research Services. It focuses on three key therapeutic areas - Oncology, Diabetes, and Immunology. Its APIs portfolio includes cardiovascular, anti-diabetics, immunosuppressants, and specialty molecules. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. Its APIs manufacturing facilities with capabilities in microbial fermentation, downstream process, including chromatographic purification, chemical synthesis, peptide synthesis and Highly Potent APIs (HPAPIs). It has over five facilities in Bangalore, Hyderabad and Visakhapatnam in India.